

The Executive Office of Health & Human Services

Pharmacy and Therapeutics Committee Meeting Minutes



Tuesday, September 9, 2019

8:00 AM

DXC Technology

301 Metro Center Blvd, Room 203

Warwick, Rhode Island 02886

P & T Members Present: Greg Allen, MD
Todd Brothers, PharmD
Dave Feeney, RPh, Chairperson
Matt Salisbury, MD
Rick Wagner, MD
Tracey Taviera, PharmD

Absent: Scott Campbell, RPh

Others Present: Ann Bennett (DXC Technology)
Jerry Fingerut, MD (EOHHS)
Karen Mariano, RPh (DXC Technology)
Kathryn Novak, RPh (Magellan Medicaid Administration)

The meeting was called to order by the Chairperson once a quorum was in attendance - 8:08 am.

The June 4th, 2019 meeting minutes were reviewed and by vote were accepted as presented.

Public testimony included the following speakers and topic:

1. Samaneh Kalirai, BMS. Oencia.
2. Sarah Hnath, Abbvie, Skyrizi.
3. Elizabeth Lubelczyk, Lilly. Taltz.
4. Tom Algozzine, Novartis. Cosentyx.
- 5.

Magellan Medicaid Administration (MMA) presented the following categories for therapeutic class reviews with discussion from the pharmacy and therapeutics committee.

1. Alzheimer Agents. No new relevant clinical information. Motion made to accept the recommendations as presented; unanimously approved.
2. Analgesics, Narcotic Long Acting. FDA safety communications on rapid discontinuation. CDC clarified 2016 guidelines when prescribing for chronic pain. Discussion: this topic routinely discussed by DUR. Motion made to accept the recommendations as presented; unanimously approved.
3. Analgesics, Short Acting. New product, Dsuvia, to be used in a healthcare setting, maximum of 72 hours. New formulations Apadaz new strengths 4.08/325 and 8.16/325. Recommend add the Tramadol/APAP formulations. Why recommendations the combination product. It was on in the past, then off based on cost, but now again cost effective. Motion made to accept the recommendations as presented; unanimously approved.
4. Androgenic Agents. Do we have any edits on the use of the androgenic agents? Informational edit at POS to the pharmacies. Motion made to accept the recommendations as presented; unanimously approved.
5. Antiparkinson's Agents. New products, Inbrija (levodopa inhalation powder). Motion made to accept the recommendations as presented; unanimously approved.
6. Benign Prostatic Hypertension Agents. No changes to the class. Motion made to accept the recommendations as presented; unanimously approved.
7. Bladder relaxants. Nothing new; no changes to the PDL. Motion made to accept the recommendations as presented; unanimously approved.
8. Cytokine and Calmodulin Antagonists. New information Skyrizi; updated indications: Actemra, Cimzia, Inflectra, Renflexis, Otezla. New formulations: Actemra 162mg/0.9ml as ACTPen. Tremfya single dose prefilled auto-injector. Guideline & safety updates: FDA – Xeljanz and the XR, ACR/ NPF and AAD/NPF. Request review of this group of medications at the April 2020 meeting. Motion made to accept the recommendations as presented; unanimously approved.
9. Erythropoietins. ASCO and ASH updated their 2010 recommendations for the use of ESAs in patients with cancer. Recommended change in the category to Retacrit (biosimilar). Consistent with the philosophy of the PDL, patients established on Procrit will be grandfathered if they have used Procrit in the past year. Recommending Retacrit for the new starts. Motion made to accept the recommendations as presented; unanimously approved.
10. Ophthalmic Agents.

- a. Allergic Conjunctivitis. Two products being discontinued. No changes. Motion made to accept the recommendations as presented; unanimously approved.
 - b. Antibiotics. No changes. Motion made to accept the recommendations as presented; unanimously approved.
 - c. Antibiotics-Steroid Combinations. No changes. Motion made to accept the recommendations as presented; unanimously approved.
 - d. Anti-inflammatory. New formulations Inveltys (loteprednol etabonate) and Dextenza (dexamethasone insert), will not expect to see the insert dispensed/billed at the point of service (retail) pharmacy. No changes. Motion made to accept the recommendations as presented; unanimously approved.
 - e. Anti-inflammatory, Immunomodulators. New formulation Cequa (cyclosporine ophthalmic solution). Motion made to accept the recommendations as presented; unanimously approved.
 - f. Glaucoma. New formulations Xelpros (latanoprost) and Rocklatan (netarsudil and latanoprost). Glad to see category expanding. Motion made to accept the recommendations as presented; unanimously approved.
11. Otic Agents
- a. Antibiotics. No changes. Discussion/question: the cost of the ciprofloxacin ophthalmic compared to otic product? Are these really the same product? Motion made to accept the recommendations as presented; unanimously approved.
 - b. Anti-infectives and Anesthetics. Motion made to accept the recommendations as presented; unanimously approved.
 - c. Anti-inflammatory. Motion made to accept the recommendations as presented; unanimously approved.
12. Phosphate Binders. Motion made to accept the recommendations as presented; unanimously approved.
13. Stimulants and Related Agents. New generics, Evekeo. New formulations: Jornay PM (methylphenidate), Evekeo ODT and Adhansia XR. New products. Sunosi (solriamfetol). Discussion; has DUR evaluated total daily dose and total number of tablets? And develop guidelines, quantity limits? What percent are done by desk review compared to the point of service automated prior authorization? Comment; ACAP question regarding a uniform formulary/PDL across all of Medicaid. Motion made to accept the recommendations as presented; unanimously approved.
14. Antihypertensive, Sympatholytics. No changes. Motion made to accept the recommendations as presented; unanimously approved.

2019 Meeting Schedule – 8:00 am

December 17th

2020 Proposed Schedule

April 7th

June 9th

September 15th

December 15th

Adjournment

The meeting adjourned at 9:40 AM